Canada/Europe, 2 February 2022 – Canadian CRO IonsGate Preclinical Services Inc (IonsGate), that is a market leader in preclinical research services, and European life sciences company InSilicoTrials just announced a partnership to leverage innovative technology like Modeling and Simulation.
IonsGate and InSilicoTrials are going to work together in order to optimize preclinical studies relying on innovation and digitalization, as recommended by regulatory bodies – such as FDA and EMA.
InSilicoTrials will provide a complex technology known as Modeling and Simulation to digitalize IonsGate’s drug discovery processes. This will significantly cut the cost and timeframe of preclinical tests while increasing the safety of new molecules.
IonsGate has been conducting ion channels/cell-based assays and tissue-based assays for many years now. Its mission is to characterize proprietary compounds with an integrative approach to cardiac safety and function. IonsGate’s team of experts in drug safety and discovery is constantly helping pharmaceutical companies with experimental design, production and interpretation of data, and guidance for next step in the drug discovery process.
InSilicoTrials is the first cloud-based platform that provides healthcare companies with easy-to-use tools to perform computational Modeling and Simulation in drug discovery and development. Simulation is a key factor to cut in vitro and in vivo test costs and shorten the go-to-market of new medicines. This enables pharmaceutical companies and CROs to free resources, do more reseach and in the long run find a higher number of new molecules to treat more diseases.
This partnership will allow to combine IonsGate’s in vitro services with InSilicoTrials’ in silico solutions in a cost-effective and highly reliable way, with the objective of accelerating innovation in drug discovery, for the benefit of thousands of patients worldwide.
Full Press Release:
https://lifesciencesbc.ca/members/ionsgate-preclinical-services-and-insilicotrials-form-partnership/